InMed Pharma Q1 Revenue Plunges 48%, Net Loss Widens, Exits Commercial Ops Amid Delisting Risk
INM sits 26% above its 52-week low of $0.575 on light trading volume (0.2× avg).
Summary
InMed Pharmaceuticals reported Q1 2026 results with revenue of $660K, a significant 47.7% decrease year-over-year, and a net loss of $2.97M, widening from the prior year. The company announced it is winding down its BayMedica commercial operations, which was its revenue-generating segment, to refocus on its pharmaceutical pipeline. This strategic shift, coupled with a Nasdaq notice for its sub-$1 share price and a cash runway only into Q4 2026, underscores severe financial and operational challenges. This news reinforces the 'going concern' warning previously disclosed and highlights the urgent need for substantial additional financing or strategic transactions to continue development programs and maintain its public listing.
At the time of this announcement, INM was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.58 to $7.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.